What is Zai Lab's upcoming event about?

Zai Lab will hold a conference call and webcast on October 24, 2024, to discuss data from a Phase 1 clinical trial of ZL-1310.

When is the conference call and webcast scheduled?

The conference call and webcast will take place at 8:30 a.m. ET (8:30 p.m. HKT) on October 24, 2024.

Is advance registration required to participate in the conference call?

Participants must register in advance to access the conference call and webcast.

How can participants access the live webcast?

Listeners can access the live webcast by visiting Zai Lab's investor relations website.

What areas does Zai Lab focus on in its research and development?

Zai Lab is focused on developing innovative products in areas like oncology, immunology, neuroscience, and infectious disease, targeting significant unmet medical needs.

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

10/17/24 8:00:00 AM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZLAB alert in real time by email

Company to host conference call and webcast on October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT), following plenary oral presentation of data at the EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company's investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT).

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.

Details are as follows:

Registration Link: https://register.vevent.com/register/BI6f8ba8dc42d04cd3afd7095cf7c83d40

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

A replay will be available shortly after the call and can be accessed by visiting the Company's website.

About Zai Lab

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241017107131/en/

Get the next $ZLAB alert in real time by email

Recent Analyst Ratings for

$ZLAB

Date	Price Target	Rating	Analyst
3/7/2025	$55.00	Sector Outperform	Scotiabank
3/3/2025	$29.00 → $36.10	Buy → Neutral	BofA Securities
12/14/2023	$47.50	Overweight	Morgan Stanley
8/10/2023	$70.00	Overweight	Cantor Fitzgerald
3/2/2022	$194.00 → $102.00	Outperform	SVB Leerink
1/21/2022	$64.00	Outperform	Macquarie
12/15/2021	$189.00 → $136.00	Overweight	JP Morgan
11/11/2021	$222.00 → $217.00	Buy	Citigroup

More analyst ratings

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Chat with this insight

Q&A

What is Zai Lab's upcoming event about?

When is the conference call and webcast scheduled?

Is advance registration required to participate in the conference call?

How can participants access the live webcast?

What areas does Zai Lab focus on in its research and development?

Recent Analyst Ratings for $ZLAB

$ZLAB Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

$ZLAB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chairperson & CEO Du Ying exercised 96,389 units of American Depositary Shares at a strike of $0.60 and sold $2,731,507 worth of American Depositary Shares (96,389 units at $28.34) (SEC Form 4)

Director Morrison Scott W sold $715,086 worth of American Depositary Shares (23,799 units at $30.05), decreasing direct ownership by 50% to 23,702 units (SEC Form 4)

Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $0.60 and sold $2,953,308 worth of American Depositary Shares (100,000 units at $29.53) (SEC Form 4)

$ZLAB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Scotiabank initiated coverage on Zai Lab with a new price target

Zai Lab downgraded by BofA Securities with a new price target

Morgan Stanley initiated coverage on Zai Lab with a new price target

$ZLAB Leadership Updates

Live Leadership Updates

$ZLAB Press Releases

Fastest customizable press release news feed in the world

$ZLAB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ZLAB SEC Filings

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Zai Lab Announces Participation in Investor Conferences in June 2025

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

SEC Form 144 filed by Zai Lab Limited

$ZLAB Financials

Live finance-specific insights

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Recent Analyst Ratings for
$ZLAB

$ZLAB
Large Ownership Changes

$ZLAB
Insider Trading

$ZLAB
Analyst Ratings

$ZLAB
Leadership Updates

$ZLAB
Press Releases

$ZLAB
Insider Purchases

$ZLAB
SEC Filings

$ZLAB
Financials